HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia

BACKGROUND: Myelodysplastic syndrome (MDS) can progress to acute myeloid leukemia (AML), and conventional chemotherapy (decitabine) does not effectively inhibit tumor cells. Enhancer of zeste homologue 2 (EZH2) and Heme oxygenase-1 (HO-1) are two key factors in patients resistance and deterioration....

Descripción completa

Detalles Bibliográficos
Autores principales: He, Zhengchang, Zhang, Siyu, Ma, Dan, Fang, Qin, Yang, Liping, Shen, Shaoxian, Chen, Ying, Ren, Lingli, Wang, Jishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849246/
https://www.ncbi.nlm.nih.gov/pubmed/31711520
http://dx.doi.org/10.1186/s12967-019-2115-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849246/
https://www.ncbi.nlm.nih.gov/pubmed/31711520
http://dx.doi.org/10.1186/s12967-019-2115-9

Ejemplares similares